Healthcare Industry News: Medegen
News Release - September 17, 2007
Medegen Responds to U.S. Federal Court's Decision in ICU Medical Inc. Patent Infringement Case
Medegen Intends to Appeal Decision; Will Continue to Protect Its InnovationONTARIO, Calif.--(HSMN NewsFeed)--In response to today's motion granted by the U.S. Federal Court for non-infringement in favor of ICU Medical Inc. (NASDAQ: ICUI ), Medegen, Inc. announced it will appeal the decision.
Medegen continues to believe that ICU Medical's valve product, CLC-2000(TM), infringes on the company's patent for its proprietary valve technology. "We are very disappointed by and disagree with the Court's decision," said Jeff Goble, President of Medegen. "We intend to pursue an appeal, and are confident in our chances of prevailing on such appeal."
About Medegen, Inc.
Medegen is a leading innovator in infusion therapy, focused on helping hospitals drive greater clinical performance for improved patient care. The growing company provides clinically superior medical products and reliable, cost-effective manufacturing services to the medical community through its three operating units: Manufacturing Services, Maximus and KippMed. Manufacturing Services provides cost-effective contract manufacturing solutions to medical device and pharmaceutical companies. KippMed manufactures and markets IV therapy components for the OEM market, drawing from a 25-year history in IV component supply. Maximus develops, manufactures and markets needleless intravenous therapy products for the acute care market. The Maximus line of medical products features patent-protected technologies which improve patient outcomes and greatly reduce bloodstream infection rates. Medegen is headquartered in Ontario, Calif. and has operations in Tijuana, Mexico. For more visit http://www.maximusmedical.com.
Source: Medegen
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
